Xynomic, a US-China oncology pharma, recently completed a pre-IND meeting with the US FDA for its pan-RAF inhibitor XP-102. It said the FDA provided valuable advice on its clinical development plan for the candidate. The company, which thinks XP-102 may prove to be best-in-class, hopes to file for XP-102 in the second half of 2019. In 2017, Xynomic announced a $502 million agreement to acquire global rights to the molecule from Boehringer Ingelheim.
Source: China Biotoday
